| Autor: |
Cortijo Cascajares S; Servicio de Farmacia, Hospital Universitario 12 de Octubre, Madrid. susancortijo@yahoo.es, García Rodríguez MP, Campo Angora M, Serrano Garrote O, Herreros de Tejada A |
| Jazyk: |
Spanish; Castilian |
| Zdroj: |
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria [Farm Hosp] 2004 May-Jun; Vol. 28 (3), pp. 192-200. |
| Abstrakt: |
Psoriasis is an inflammatory disease mediated by immune system T cells. The use of current systemic immunosuppressive therapies is limited by an inability to maintain disease remission safely knowledge on. Advances in recombinant DNA technology and the increase in knowledge on psoriasis immunopathology knowledge have led to the development of numerous biologic agents for the treatment of the disease. In this review the mechanisms of action for these new agents, as well as their safety profiles and efficacy data have been analyzed. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
